PE20070414A1 - Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol) - Google Patents
Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol)Info
- Publication number
- PE20070414A1 PE20070414A1 PE2006000926A PE2006000926A PE20070414A1 PE 20070414 A1 PE20070414 A1 PE 20070414A1 PE 2006000926 A PE2006000926 A PE 2006000926A PE 2006000926 A PE2006000926 A PE 2006000926A PE 20070414 A1 PE20070414 A1 PE 20070414A1
- Authority
- PE
- Peru
- Prior art keywords
- hydroxy
- water
- formulation
- carmoterol
- quinolinone
- Prior art date
Links
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 title abstract 2
- 229950010713 carmoterol Drugs 0.000 title abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 235000019800 disodium phosphate Nutrition 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000002663 nebulization Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA LIQUIDA QUE COMPRENDE: A) UNA SAL HIDROSOLUBLE DE 8-HIDROXI-5-[(1R)-1-HIDROXI-2-[[(1R)-2-(4-METOXIFENIL)-1-METILETIL]AMINO]ETIL]-2(1H)-QUINOLINONA (CARMOTEROL) TAL COMO CLORHIDRATO QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,0005 A 0,001% P/V DE LA FORMULACION; B) UN SOLVENTE TAL COMO AGUA O UNA SOLUCION ACUOSA QUE CONTIENE UN 50% V/V DE AGUA Y UN COSOLVENTE MISCIBLE EN AGUA TAL COMO PROPILENGLICOL; C) UN AGENTE AMORTIGUADOR TAL COMO EL PAR ACIDO CITRICO/CITRATO DE SODIO O EL PAR ACIDO CITRICO/FOSFATO DISODICO QUE SE ENCUENTRA EN UNA CONCENTRACION DE 2mM A 10mM EN LA FORMULACION; Y D) UN AGENTE PARA AJUSTAR LA TONICIDAD TAL COMO CLORURO DE SODIO. DICHA FORMULACION SE ADMINISTRA POR NEBULIZACION Y TIENE UN pH DE 4,0 A 5,0 SIENDO UTIL EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05016664 | 2005-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070414A1 true PE20070414A1 (es) | 2007-05-11 |
Family
ID=37564044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000926A PE20070414A1 (es) | 2005-08-01 | 2006-07-31 | Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070065366A1 (es) |
| EP (1) | EP1915129B1 (es) |
| JP (1) | JP2009502997A (es) |
| CN (1) | CN101198313A (es) |
| AR (1) | AR055363A1 (es) |
| AT (1) | ATE446739T1 (es) |
| AU (1) | AU2006275137A1 (es) |
| CA (1) | CA2617286A1 (es) |
| DE (1) | DE602006010088D1 (es) |
| EA (1) | EA013351B1 (es) |
| ES (1) | ES2332290T3 (es) |
| PE (1) | PE20070414A1 (es) |
| TW (1) | TW200735870A (es) |
| WO (1) | WO2007014673A2 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579244A (en) | 2007-02-28 | 2012-04-27 | Cipla Ltd | Process for preparing isomers of carmoterol |
| WO2011015289A1 (en) | 2009-08-04 | 2011-02-10 | Chiesi Farmaceutici S.P.A. | 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate |
| US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
| AU2011253203A1 (en) * | 2010-05-10 | 2012-11-22 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
| US10350139B2 (en) | 2011-10-25 | 2019-07-16 | Corning Incorporated | Pharmaceutical glass packaging assuring pharmaceutical sterility |
| EP2771295B1 (en) * | 2011-10-25 | 2017-11-22 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US10273048B2 (en) | 2012-06-07 | 2019-04-30 | Corning Incorporated | Delamination resistant glass containers with heat-tolerant coatings |
| CN111533441A (zh) | 2012-06-07 | 2020-08-14 | 康宁股份有限公司 | 抗脱层的玻璃容器 |
| US9034442B2 (en) | 2012-11-30 | 2015-05-19 | Corning Incorporated | Strengthened borosilicate glass containers with improved damage tolerance |
| US10117806B2 (en) | 2012-11-30 | 2018-11-06 | Corning Incorporated | Strengthened glass containers resistant to delamination and damage |
| US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CN104274392A (zh) * | 2013-07-01 | 2015-01-14 | 成都苑东药业有限公司 | 一种格隆溴铵注射液组合物及其制备方法 |
| US10899659B2 (en) | 2014-09-05 | 2021-01-26 | Corning Incorporated | Glass articles and methods for improving the reliability of glass articles |
| KR20170089905A (ko) | 2014-11-26 | 2017-08-04 | 코닝 인코포레이티드 | 강화된 및 내구성 있는 유리 용기의 생산 방법 |
| CN110376313B (zh) * | 2019-08-20 | 2022-06-07 | 广州健康元呼吸药物工程技术有限公司 | 一种检测富马酸福莫特罗或其相关制剂中杂质的方法 |
| SG10201912063PA (en) * | 2019-12-12 | 2021-07-29 | Nat Skin Centre Singapore Pte Ltd | A pharmaceutical formulation |
| CN114452250A (zh) * | 2021-12-14 | 2022-05-10 | 澳美制药(苏州)有限公司 | 盐酸丙卡特罗口服液及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| US20030215396A1 (en) * | 1999-09-15 | 2003-11-20 | Boehringer Ingelheim Pharma Kg | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| ATE526967T1 (de) * | 2003-07-31 | 2011-10-15 | Boehringer Ingelheim Int | Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum |
| MX2007012084A (es) * | 2005-03-30 | 2007-11-21 | Schering Corp | Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada. |
-
2006
- 2006-07-25 JP JP2008524398A patent/JP2009502997A/ja not_active Withdrawn
- 2006-07-25 WO PCT/EP2006/007322 patent/WO2007014673A2/en not_active Ceased
- 2006-07-25 CA CA002617286A patent/CA2617286A1/en not_active Abandoned
- 2006-07-25 AT AT06762809T patent/ATE446739T1/de active
- 2006-07-25 ES ES06762809T patent/ES2332290T3/es active Active
- 2006-07-25 AU AU2006275137A patent/AU2006275137A1/en not_active Abandoned
- 2006-07-25 EP EP06762809A patent/EP1915129B1/en active Active
- 2006-07-25 DE DE602006010088T patent/DE602006010088D1/de active Active
- 2006-07-25 CN CNA2006800218594A patent/CN101198313A/zh active Pending
- 2006-07-25 EA EA200800142A patent/EA013351B1/ru not_active IP Right Cessation
- 2006-07-28 US US11/494,737 patent/US20070065366A1/en not_active Abandoned
- 2006-07-31 PE PE2006000926A patent/PE20070414A1/es not_active Application Discontinuation
- 2006-07-31 TW TW095127952A patent/TW200735870A/zh unknown
- 2006-07-31 AR ARP060103337A patent/AR055363A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070065366A1 (en) | 2007-03-22 |
| WO2007014673A3 (en) | 2007-07-19 |
| WO2007014673A2 (en) | 2007-02-08 |
| AU2006275137A1 (en) | 2007-02-08 |
| EA200800142A1 (ru) | 2008-08-29 |
| EP1915129A2 (en) | 2008-04-30 |
| ES2332290T3 (es) | 2010-02-01 |
| AR055363A1 (es) | 2007-08-22 |
| EA013351B1 (ru) | 2010-04-30 |
| CN101198313A (zh) | 2008-06-11 |
| CA2617286A1 (en) | 2007-02-08 |
| DE602006010088D1 (de) | 2009-12-10 |
| EP1915129B1 (en) | 2009-10-28 |
| JP2009502997A (ja) | 2009-01-29 |
| TW200735870A (en) | 2007-10-01 |
| ATE446739T1 (de) | 2009-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070414A1 (es) | Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol) | |
| ES2244831T5 (es) | Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica | |
| ES3011984T3 (en) | Treatment of erectile dysfunction | |
| JP2011201907A5 (es) | ||
| BRPI0415470A (pt) | preparação em aerossol aquosa | |
| CA2382886A1 (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| RU2361593C3 (ru) | Комбинация азеластина и стероидов | |
| CN101506143A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的对乙酰氨基酚及其相关化合物的前药 | |
| JP2016513690A (ja) | シルデナフィルおよび他のホスホジエステラーゼ５阻害剤の経皮送達 | |
| EA200501001A1 (ru) | Фармацевтический состав с нерастворимым активным агентом | |
| ATE311174T1 (de) | Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung | |
| EA200501105A1 (ru) | Фармацевтическая композиция | |
| MX2009003002A (es) | Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco. | |
| JP2013513612A5 (es) | ||
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств | |
| PE20030970A1 (es) | Formulacion de aerosol para inhalacion que contiene una sal de tiotropio | |
| EA200601578A1 (ru) | Стабильные фармацевтические растворы для дозированных ингаляторов под давлением | |
| Salehi et al. | Absorption enhancer approach for protein delivery by various routes of administration: a rapid review | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| ES2312921T3 (es) | Disolucion acuosa concentrada de ambroxol. | |
| AR043536A1 (es) | Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico | |
| PE20070353A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| ES2791775A2 (es) | Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |